China NMPA Drug Inspection - Langzhi Group Shuangren Pharmaceutical Co., Ltd. - Big hawthorn pill

The Ningxia Hui Autonomous Region Drug Administration announced the results of its regional drug sampling inspections conducted in 2019, with the findings published on January 22, 2020. This comprehensive regulatory oversight covered a total of 150 batches across 44 drug varieties, encompassing chemical drugs, traditional Chinese medicine (TCM) preparations, and TCM decoction pieces from various pharmaceutical manufacturers and distributors. The inspections were carried out in strict adherence to the "Drug Administration Law of the People's Republic of China," the "Regulations on the Administration of Drug Quality Sampling Inspection," and various official drug standards, including the Chinese Pharmacopoeia (2015 Edition) and specific Ministry of Health and regional TCM processing standards. Notably, the report confirmed that all sampled drugs met the required quality and safety standards. Consequently, no violations or non-compliant items were identified during this sampling round. This positive outcome signifies effective adherence to regulatory requirements within the regional pharmaceutical sector, ensuring the quality and safety of medicines available to the public. No specific enforcement actions or corrective measures were mandated, given the full compliance of all tested products.